Gut microbiota therapy for nonalcoholic fatty liver disease: Evidence from randomized clinical trials
Nonalcoholic fatty liver disease (NAFLD) has a high prevalence worldwide, but there are no medications approved for treatment. Gut microbiota would be a novel and promising therapeutic target based on the concept of the gut–liver axis in liver disease. We reviewed randomized controlled trials on gut...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-01-01
|
| Series: | Frontiers in Microbiology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmicb.2022.1004911/full |
| _version_ | 1797952081567416320 |
|---|---|
| author | Ting-Rui Han Wen-Juan Yang Wen-Juan Yang Qing-Hua Tan Qing-Hua Tan Shuai Bai Huang Zhong Yang Tai Huan Tong Huan Tong |
| author_facet | Ting-Rui Han Wen-Juan Yang Wen-Juan Yang Qing-Hua Tan Qing-Hua Tan Shuai Bai Huang Zhong Yang Tai Huan Tong Huan Tong |
| author_sort | Ting-Rui Han |
| collection | DOAJ |
| description | Nonalcoholic fatty liver disease (NAFLD) has a high prevalence worldwide, but there are no medications approved for treatment. Gut microbiota would be a novel and promising therapeutic target based on the concept of the gut–liver axis in liver disease. We reviewed randomized controlled trials on gut microbiota therapy in NAFLD in this study to evaluate its efficacy and plausibility in NAFLD. |
| first_indexed | 2024-04-10T22:41:53Z |
| format | Article |
| id | doaj.art-9100b5f959244b14ae4292d7f905098f |
| institution | Directory Open Access Journal |
| issn | 1664-302X |
| language | English |
| last_indexed | 2024-04-10T22:41:53Z |
| publishDate | 2023-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Microbiology |
| spelling | doaj.art-9100b5f959244b14ae4292d7f905098f2023-01-16T04:47:39ZengFrontiers Media S.A.Frontiers in Microbiology1664-302X2023-01-011310.3389/fmicb.2022.10049111004911Gut microbiota therapy for nonalcoholic fatty liver disease: Evidence from randomized clinical trialsTing-Rui Han0Wen-Juan Yang1Wen-Juan Yang2Qing-Hua Tan3Qing-Hua Tan4Shuai Bai5Huang Zhong6Yang Tai7Huan Tong8Huan Tong9West China School of Medicine, Sichuan University, Chengdu, ChinaDepartment of Gastroenterology, West China Hospital, Sichuan University, Chengdu, ChinaLab of Gastroenterology and Hepatology, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Gastroenterology, West China Hospital, Sichuan University, Chengdu, ChinaLab of Gastroenterology and Hepatology, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Gastroenterology, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Gastroenterology, Zigong First People’s Hospital, Zigong, ChinaLab of Gastroenterology and Hepatology, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Gastroenterology, West China Hospital, Sichuan University, Chengdu, ChinaLab of Gastroenterology and Hepatology, West China Hospital, Sichuan University, Chengdu, ChinaNonalcoholic fatty liver disease (NAFLD) has a high prevalence worldwide, but there are no medications approved for treatment. Gut microbiota would be a novel and promising therapeutic target based on the concept of the gut–liver axis in liver disease. We reviewed randomized controlled trials on gut microbiota therapy in NAFLD in this study to evaluate its efficacy and plausibility in NAFLD.https://www.frontiersin.org/articles/10.3389/fmicb.2022.1004911/fullnon-alcoholic fatty liver diseasegut microbiotarandomized clinical trialprobioticsprebioticssynbiotics |
| spellingShingle | Ting-Rui Han Wen-Juan Yang Wen-Juan Yang Qing-Hua Tan Qing-Hua Tan Shuai Bai Huang Zhong Yang Tai Huan Tong Huan Tong Gut microbiota therapy for nonalcoholic fatty liver disease: Evidence from randomized clinical trials Frontiers in Microbiology non-alcoholic fatty liver disease gut microbiota randomized clinical trial probiotics prebiotics synbiotics |
| title | Gut microbiota therapy for nonalcoholic fatty liver disease: Evidence from randomized clinical trials |
| title_full | Gut microbiota therapy for nonalcoholic fatty liver disease: Evidence from randomized clinical trials |
| title_fullStr | Gut microbiota therapy for nonalcoholic fatty liver disease: Evidence from randomized clinical trials |
| title_full_unstemmed | Gut microbiota therapy for nonalcoholic fatty liver disease: Evidence from randomized clinical trials |
| title_short | Gut microbiota therapy for nonalcoholic fatty liver disease: Evidence from randomized clinical trials |
| title_sort | gut microbiota therapy for nonalcoholic fatty liver disease evidence from randomized clinical trials |
| topic | non-alcoholic fatty liver disease gut microbiota randomized clinical trial probiotics prebiotics synbiotics |
| url | https://www.frontiersin.org/articles/10.3389/fmicb.2022.1004911/full |
| work_keys_str_mv | AT tingruihan gutmicrobiotatherapyfornonalcoholicfattyliverdiseaseevidencefromrandomizedclinicaltrials AT wenjuanyang gutmicrobiotatherapyfornonalcoholicfattyliverdiseaseevidencefromrandomizedclinicaltrials AT wenjuanyang gutmicrobiotatherapyfornonalcoholicfattyliverdiseaseevidencefromrandomizedclinicaltrials AT qinghuatan gutmicrobiotatherapyfornonalcoholicfattyliverdiseaseevidencefromrandomizedclinicaltrials AT qinghuatan gutmicrobiotatherapyfornonalcoholicfattyliverdiseaseevidencefromrandomizedclinicaltrials AT shuaibai gutmicrobiotatherapyfornonalcoholicfattyliverdiseaseevidencefromrandomizedclinicaltrials AT huangzhong gutmicrobiotatherapyfornonalcoholicfattyliverdiseaseevidencefromrandomizedclinicaltrials AT yangtai gutmicrobiotatherapyfornonalcoholicfattyliverdiseaseevidencefromrandomizedclinicaltrials AT huantong gutmicrobiotatherapyfornonalcoholicfattyliverdiseaseevidencefromrandomizedclinicaltrials AT huantong gutmicrobiotatherapyfornonalcoholicfattyliverdiseaseevidencefromrandomizedclinicaltrials |